Company: ARVN
Filing Date: 2025-02-11
Form Type: 10-K
Source: 0001655759-25-000016
Chunk: 276

Company: ARVINAS, INC.
Filing Date: 2025-02-11
Form: 10-K
Item: Item 1A
Chunk 276
---
 investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any legal, regulatory or administrative actions or proceedings are instituted against us, and we are not successful in defending ourselves or asserting our rights, such actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diversion of management attention, general costs of litigation or proceedings, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. 

Risks Related to Our Common Stock

The price of our common stock is volatile and may fluctuate substantially, which could result in the loss of all or part of our stockholders’ investment. 

Our stock price has been and likely will continue to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: 

•the degree of success of any competitive products or technologies; 

•results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors; 

•regulatory or legal developments in the United States and other countries; 

•developments or disputes concerning patent applications, issued patents or other proprietary rights; 

•the recruitment or departure of key personnel; 

•the level of expenses related to any of our product candidates or clinical development programs; 

•the results of our efforts to discover, develop, acquire or in-license additional technologies or product candidates; 

123

•actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; 

•variations in our financial results or those of companies that are perceived to be similar to us; 

•changes in the structure of healthcare payment systems in the United States and other jurisdictions; 

•market conditions in the pharmaceutical and biotechnology sectors; 

•general economic, industry and market conditions, including geopolitical conflicts, inflation and high interest rates; and 

•the other factors described in this “Risk Factors” section. 

If any of the foregoing factors were to occur, or if our operating results fall below the